Transplantation in chronic myeloid leukaemia [9]

Lancet

Volumn 359, Issue 9307, 2002, Pages 712-713

  Gratwohl, A ^a   Baldomero, H ^b   Urbano Ispizua, A ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b EBMT Secretariat   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; LETTER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0037160772     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07831-5     Document Type: Letter

References (3)

1. Hematopoietic stem cell transplantation activity in Europe
2. Targeting the BCR-AbL tyrosine kinase in chronic myeloid leukemia
3. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer